Newly Discovered Biomarkers May Lead to Promising Diagnostic Tool for Alzheimer’s
Approach could offer stage-specific prognosis, open door to better treatment
Diagnosing Alzheimer’s disease and determining a patient’s prognosis is an inexact business, and that stands in the way of better personalized care and advances in treatment.
First, the team of researchers discovered new physical biomarkers that could help pinpoint a diagnosis – changes to proteins found in the spinal fluid and blood of patients. In particular, as Alzheimer’s severity increased, the proteins were longer, more rigid and more clustered, said lead researcher Mingjun Zhang, a professor of biomedical engineering at Ohio State.
Click here to read more.
NeuroSafe 2019 Symposium
Aug. 8-9, 2019; Minneapolis
SNSA Congress 2019
Aug. 8-11, 2019; Cape Town, South Africa
2019 Managing Coding and Reimbursement Challenges
Aug. 22-24, 2019; Rosemont, Ill.
2019 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 28-31, 2019; Orlando, Fla.
Sept. 8-11, 2019; Leuven, Belgium